US-based health tech startup, LifePlus Inc. has announced that they have developed the world’s first non-invasive continuous blood glucose monitoring multi-sensor wearable device.
According to LifePlus, in addition to blood glucose monitoring, the patent-pending multi-sensor device, called LifeLeaf, non-invasively monitors heart rate, blood pressure, respiration rate and oxygen saturation.
The wearable is intended to help users continuously and non-invasively monitor and tracks chronic health risks such as diabetes, cardiac arrhythmia, congestive heart failure, COPD, sleep apnoea and hypertension.
“We have been in stealth mode and we are thrilled to announce the introduction of LifeLeaf as part of the burgeoning medical wearables category,” said Trobough.
“Managing diabetes and other chronic diseases requires early and timely detection, rapid intervention and high compliance. LifeLeaf exceeds those requirements with its patent-pending open standards-based software stack and cloud-based analytics. LifeLeaf is different from any other product and software technology available – it is truly unique and we are excited to make this multi-sensor capability available to companies and developers globally,” continued Trobough.
According to LifePlus, LifeLeaf is a cloud-based AI solution with a user-interface that is simple and easy to use, as well as a connected mobile app that provides cloud-based analytics with real-time notifications.
The wearable is based on an open standards based-software stack that is also available to license. The product is targeted at the multi-billion-dollar medical wearables market, with an emphasis on the self-monitoring blood glucose market.
The company also announced that LifeLeaf is currently active in five trials around the world, and will be commercially available later this year.